logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
20/09/2025
The International Monetary Fund (IMF) stated that it expects Mexico's economic growth rate to accelerate to 1.5% in 2026.
Latest
3 m ago
GoodRx's stock price hit an intraday low, falling 6.6% at one point.
4 m ago
Nancy Ibach, Vice President of the Oncology Department of Merck USA, stated that their cancer therapy Keytruda, in its new subcutaneous injection form called Keytruda Qlex, can be administered in just one to two minutes, depending on the dosage, while intravenous infusion typically takes about 30 minutes.
4 m ago
Nancy Ibach, Vice President of the Oncology Business Unit of MSD USA, stated that their cancer therapy Keytruda subcutaneous injection new dosage form is branded as Keytruda Qlex. Depending on the dosage, administration can be completed in just one to two minutes, whereas intravenous infusion typically takes about 30 minutes.
4 m ago
The US dollar index rose by 0.3% on Friday, with a V-shaped reversal for the week.
5 m ago
The US FDA has approved Merck's blockbuster cancer therapy Keytruda in subcutaneous injection form. Analysts say this marks a significant change in the dosing method of this globally top-selling cancer immunotherapy, with the potential to improve patient experience and clinical efficiency. This move is also seen as a strategic component of Merck's defense of Keytruda's market share as competition from biosimilars intensifies.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.